2020
DOI: 10.1155/2020/8820538
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis

Abstract: Asherman’s Syndrome (AS) is an uncommon, acquired, and refractory gynecological disorder. Current treatment was still limited, and stem cell-based therapy has been proposed as a novel strategy for management of AS. Here, we conducted a meta-analysis of self-controlled clinical trials to assess the effectiveness and safety of stem cell-based therapy in Asherman syndrome patients who have failed in conventional treatment. We systematically searched PubMed, Embase, Cochrane, and Web of Science database (published… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 22 publications
(11 citation statements)
references
References 37 publications
0
10
0
1
Order By: Relevance
“…Severe recurrent IUA hinders embryos implantation and leads to miscarriage 50 . The primary goal of IUA treatment is to restore endometrial regeneration, and stem cell-based therapy has become one of the promising adjuvant therapies for IUA treatment 51 . Substantial progress has been made in preclinical and clinical studies of using UC-MSCs for the treatment of IUA.…”
Section: Discussionmentioning
confidence: 99%
“…Severe recurrent IUA hinders embryos implantation and leads to miscarriage 50 . The primary goal of IUA treatment is to restore endometrial regeneration, and stem cell-based therapy has become one of the promising adjuvant therapies for IUA treatment 51 . Substantial progress has been made in preclinical and clinical studies of using UC-MSCs for the treatment of IUA.…”
Section: Discussionmentioning
confidence: 99%
“…Some researchers evaluated the biosafety of MenSCs transplantation in animal model of IUA, especially paying attention to toxicity and tumorigenicity, the results suggesting that MenSCs transplantation is safe for rat model of IUA ( 9 ). One meta-analysis systematically reviewed also suggested that MenSCs transplantation is safe for IUA treatment by prolonging menstruation duration and recovering endometrial thickness ( 45 ). However, research on the safety of MenSCs transplantation is not enough, and whether graft-vs.-host disease, adverse reactions or malignant transformation will occur after transplantation remains to be observed for a long time.…”
Section: Safety Of Menscs Transplantationmentioning
confidence: 99%
“…Метод їх уведення залежить від гостроти фази запалення: при гострій фазі -внутрішньоматково, при хронічній -внутрішньоочеревинно чи внутрішньовенно [16,18,20,22,24]. Ефект лікування стовбуровими клітинами у вигляді потовщення ендометрію стає найбільш вираженим за 6-9 місяців після їх застосування, а поєднання MSCs та естрогенів є нешкідливим та ефективним методом для покращення тривалості менструацій, збільшення товщини ендометрію та підвищення частоти настання вагітності [17,30]. Ефект сумісного застосування MSCs та естрогенів реалізується за допомогою IGF-1 [11].…”
Section: вступunclassified